within Pharmacolibrary.Drugs.ATC.M;

model M02AA09
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M02AA09</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bufexamac is a non-steroidal anti-inflammatory drug (NSAID) that was primarily used topically for the treatment of eczema and dermatitis. It exhibited anti-inflammatory and analgesic effects when applied to the skin. However, due to concerns about severe allergic contact dermatitis and limited efficacy, bufexamac has been withdrawn or is no longer approved for use in many countries.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic (PK) parameters or comprehensive PK models for bufexamac in humans are available in the scientific literature. Estimates below are based on general pharmacological properties of topical NSAIDs.</p><h4>References</h4><ol><li><p>Larson, DL, &amp; Lombardino, JG (1980). The topical anti-inflammatory effects of piroxicam in rodents. <i>Agents and actions</i> 10(3) 246–251. DOI:<a href=&quot;https://doi.org/10.1007/BF02025943&quot;>10.1007/BF02025943</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7405751/&quot;>https://pubmed.ncbi.nlm.nih.gov/7405751</a></p></li><li><p>Trommer, H, &amp; Neubert, RH (2005). Screening for new antioxidative compounds for topical administration using skin lipid model systems. <i>Journal of pharmacy &amp; pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</i> 8(3) 494–506. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16401395/&quot;>https://pubmed.ncbi.nlm.nih.gov/16401395</a></p></li><li><p>Brogden, RN, et al., &amp; Avery, GS (1975). Bufexamac: a review of its pharmacological properties and therapeutic efficacy in inflammatory dermatoses. <i>Drugs</i> 10(5-6) 351–356. DOI:<a href=&quot;https://doi.org/10.2165/00003495-197510050-00005&quot;>10.2165/00003495-197510050-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1204506/&quot;>https://pubmed.ncbi.nlm.nih.gov/1204506</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M02AA09;
